What is your analysis of the two major CV outcome trials and from a mortality end point perspective in what way do mortality outcome end points/results distinguish the ODYSSEY Outcomes Trial with alirocumab?

What is your analysis of the two major CV outcome trials and from a mortality end point perspective in what way do mortality outcome end points/results distinguish the ODYSSEY Outcomes Trial with alirocumab?

Get Credit

What is your analysis of the two major CV outcome trials and from a mortality end point perspective in what way do mortality outcome end points/results distinguish the ODYSSEY Outcomes Trial with alirocumab?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Lawrence Leiter, MD, FRCP(C), FACP

Lawrence Leiter, MD, FRCP(C), FACP

Head, Division of Endocrinology and Metabolism Director, Lipid Clinic Associate Director, Clinical Nutrition and Risk Factor Modification Centre St. Michael’s Hospital Professor of Medicine and Nutritional Sciences University of Toronto Toronto, Ontario